Muscle loss and muscle-made proteins in people with diabetes, obesity or hormone disorders
Looks at muscle loss and muscle-made proteins in adults with metabolic or hormone diseases.
Plain-language title generated from the registry record
Registry title: Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases
Key facts
- Where
- Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, BelgiumSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a metabolic or endocrine disease. It studies sarcopenia (loss of muscle mass and strength) and myokines (substances made by muscle).
- Age
- 18 Years and older
- Sex
- All sexes can join.
- Disease stage
- Metabolic or endocrine disease (no specific stage is stated).
Main reasons for not taking part
- Known myopathy (muscle disease)
- Systemic steroid use (> 1 mg/kg hydrocortisone) or exogenous Cushing's syndrome
- Psychological, family, sociological or geographical conditions that could limit following the study plan
- Cancer within the five years before the study
- Cushing's syndrome due to an ACTH-secreting tumor
Read by machine on 9 November 2026.
Where in Belgium
- Cliniques Universitaires Saint-LucWoluwe-Saint-Pierre - Sint-Pieters-Woluwe, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Trial code
- NCT07703683
- Record updated
- 14 July 2026
- Original description
Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population.Read full original descriptionShow less
Myokines as Potential Biomarkers and Drivers of Sarcopenia in Metabolic and Endocrine Diseases
Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population.
.
Inclusion: Metabolic or endocrine disease.
Exclusion: Systemic steroid use (> 1 mg/kg hydrocortisone) or exogenous Cushing's syndrome; Psychological, family, sociological or geographical conditions that could potentially limit compliance with the study protocol; History of cancer within the five years prior to the study or Cushing's syndrome due to ACTH-secreting tumor; Known myopathy.